GLUECK, REINHARD,FAZIO, AGATA,GIANINO, VIVIANA,BILLETER, MARTIN
申请号：
CA2760787
公开号：
CA2760787C
申请日:
2010.05.03
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention relates to a combined measles-malaria vaccine containingdifferent attenuated recombinantmeasles-malaria vectors comprising a heterologous nucleic acid encodingseveral Plasmodium falciparum antigens. Preferably, itrelates to viral vectors that comprise nucleic acids encoding thecircumsporozoite (CS) protein of P. falciparum, the merozoite surfaceprotein 1(MSP-I) of P. falciparum, and its derivatives (p-42； p-83-30-38) inits glycosylated and secreted forms, and apicalmembrane antigen 1(AMA1) of P. falciparum, in its anchored or secreted form.The viral vector stems from an attenuated measlesvirus, based on a strain that is used as a vaccine and is efficient indelivering the gene of interest and that binds to and infects therelevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1and the AMA1 proteins are generated from thevirus such that they will give rise to a potent immune response in mammals,preferably humans； the expression of the proteins iselevated due to human codon optimisation. Furthermore, the invention relatesto the use of the recombinant vaccine in the prophylactictreatment of malaria.
